Webinar: Highly quantitative in vitro method for mechanistic (geno)toxicity screening
In this webinar, Miltenyi Biotec and Toxys will highlight the potential of using flow cytometry for high content toxicity analysis. You will learn about the opportunities, advantages and challenges faced while performing the ToxTracker assay for mechanistic toxicity testing.
Webinar information
Identification of toxicity profile of compound is a necessity in across industries and stages of development. Mechanism based in vitroassays at the early stage can not only speed up the compound development pipeline, but also can reduce animal testing. Information about the mode-of-action of (geno)toxic compounds can be vital for both screening and regulatory applications.
In this webinar, Miltenyi Biotec and Toxys will highlight the potential of using flow cytometry for high content toxicity analysis. You will learn about the opportunities, advantages and challenges faced while performing the ToxTracker assay for mechanistic toxicity testing.
Learning objectives:
-
- In-vitro (geno)toxicity assays
- High-throughput , reliable flow cytometry to enhance genotoxicity analysis
- ToxTracker assay for multiplexed mechanistic insight of toxicity
Presentors:
Before joining Miltenyi Biotec as a Global Product Manager for Flow Cytometry Reagents in 2018, Dr. Urmi Roy worked as a Post Doc at the Helmholtz Centre Braunschweig, Germany, where she specialized in mucosal immunology/gut microbiota. She received her Ph.D. in Immunology at the TU Braunschweig in 2017.
Dr. Giel Hendriks is the founder and CEO of Toxys, a Dutch biotech company that develops and offers innovative in vitro assays for toxicological research. He completed his Ph.D in molecular cell biology at Utrecht University and worked as senior scientist in genetic toxicology at the Leiden University Medical Center
The Presenters:
Urmi Roy – Miiltenyi Biotec
Giel Hendriks – Toxys
